Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators (Q39376122)

11 September 2017

title

Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators (English)

1 reference

11 September 2017

1 reference

1 reference

11 September 2017

1 reference

11 September 2017

Catarina Xavier

1 reference

11 September 2017

Matthias D'Huyvetter

1 reference

11 September 2017

An Aerts

1 reference

11 September 2017

Ilse Vaneycken

1 reference

11 September 2017

Marlies Gijs

1 reference

11 September 2017

Nathalie Impens

1 reference

11 September 2017

Sarah Baatout

1 reference

11 September 2017

Bernard Ponsard

1 reference

11 September 2017

Vicky Caveliers

1 reference

11 September 2017

Tony Lahoutte

1 reference

11 September 2017

publication date

1 March 2012

1 reference

Contrast Media & Molecular Imaging

11 September 2017

published in

1 reference

11 September 2017

1 reference

11 September 2017

1 reference

11 September 2017

page(s)

254-264

1 reference

Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members

11 September 2017

cites work

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Biology of HER2 and its importance in breast cancer

21 January 2018

1 reference

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools

21 January 2018

1 reference

HER-2 as a target for breast cancer therapy

21 January 2018

1 reference

Clinical trials of Herceptin(trastuzumab).

21 January 2018

1 reference

Properties, production, and applications of camelid single-domain antibody fragments

21 January 2018

1 reference

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

21 January 2018

1 reference

Current and potential therapeutic uses of lanthanide radioisotopes

21 January 2018

1 reference

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

21 January 2018

1 reference

Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

21 January 2018

1 reference

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

21 January 2018

1 reference

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

21 January 2018

1 reference

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

21 January 2018

1 reference

Imaging of HER-2 overexpression in tumors for guiding therapy

21 January 2018

1 reference

Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours

21 January 2018

1 reference

Megalin and cubilin: multifunctional endocytic receptors

21 January 2018

1 reference

Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.

21 January 2018

1 reference

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMMI.491

1 reference

11 September 2017

1 reference